 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Multiple Sclerosis (MS)
An unpredictable disease of the central nervous system, multiple sclerosis (MS) can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted. Many investigators believe MS to be an autoimmune disease -- one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is the nerve-insulating myelin that comes under assault. Such assaults may be linked to an unknown environmental trigger, perhaps a virus. [Source: www.ninds.nih.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Multiple Sclerosis Study CFTY720D2309
The purpose of this clinical research study is to find out if an oral once-a-day investigational drug called fingolimod is safe and has beneficial effects in people who have relapsing-remitting Multiple Sclerosis (MS) over a two year period. Fingolimod is an oral once-a-day medicine which has not been approved yet for the treatment of patients with multiple sclerosis and is therefore not “on the market” (available for you to buy) in any country. For more information on this study, please visit www.msclinicaltrials.com. Please note that by visiting this website, you are leaving Novartis. As a resource to our visitors, Novartis may provide links to other Web sites. We try to carefully choose websites that we believe are useful and meet our high standards. However, Novartis does not control, endorse, promote, or have any affiliation with any other website unless it is expressly stated. Novartis is not responsible for the content, accuracy, or any other aspect of the information contained on such linked sites
Trial phase: Phase 3 Participation Duration: 14 visits to the study center, over a period of 24 months. Protocol Number: CFTY720D2309 |
